iCAD Appoints Dr. Robert Goodman to Board of Directors

  iCAD Appoints Dr. Robert Goodman to Board of Directors

          Renowned Radiation Oncologist Provides Clinical Leadership

Business Wire

NASHUA, N.H. -- February 24, 2014

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapies for the early
identification and treatment of cancer, today announced that Robert Goodman,
M.D., has been named to iCAD’s Board of Directors. Dr. Goodman brings nearly
50 years of clinical experience, along with extensive academic and leadership
credentials. He is the first radiation oncologist to serve on iCAD’s
multidisciplinary Board.

Robert Goodman, M.D. (Photo: Business Wire)

Robert Goodman, M.D. (Photo: Business Wire)

“Dr. Goodman’s impressive clinical background, coupled with his business
leadership experience and prestigious academic affiliations, will make him an
invaluable addition to iCAD’s Board of Directors,” said Ken Ferry, Chief
Executive Officer of iCAD, Inc. “As a highly regarded member of the radiation
oncology community, we look forward to Dr. Goodman’s guidance and insight as
we continue to grow and strengthen the Xoft business.”

Dr. Goodman is a renowned radiation oncologist who is credited with pioneering
the use of radiotherapy to treat women with breast cancer. He has served as
the Pancoast Professor and Chair of the Department of Radiation Oncology at
the University of Pennsylvania and Chair of Radiation Oncology at St. Barnabas
Medical Center. Additionally, he served two years as Acting Executive Director
of the Hospital of the University of Pennsylvania. Dr. Goodman has also held
faculty appointments at several prestigious medical schools including Harvard
Medical School and University of Pennsylvania School of Medicine. He has also
led Radiation Therapy Resident Programs at the University of Pennsylvania and
Allegheny University Hospitals.

“Electronic Brachytherapy is quickly becoming a sought after treatment option
in the field of radiation oncology,” said Dr. Goodman. “The Xoft System’s
mobile capabilities and innovative delivery technology help address some of
the most challenging issues associated with comprehensive cancer care in
today’s clinical environment. I look forward to joining iCAD’s esteemed board
members in their commitment to improving upon and expanding the availability
of advanced treatment options that play such a critical role in the lives of
cancer patients.”

Dr. Goodman has been published extensively in highly respected peer-reviewed
journals and has been recognized by Castle-Connolly, Good Housekeeping and
Redbook as one of the top physicians in America. He has also consistently been
named as a “Top Doctor” by New York Magazine, New Jersey Monthly and New
Jersey Life, among other publications.

Dr. Goodman is a Phi Beta Kappa graduate of Dartmouth College and received his
medical degree from the College of Physicians and Surgeons of Columbia
University. He trained in Internal Medicine and Radiation Oncology at Harvard
University and is triple-boarded in Internal Medicine, Medical Oncology and
Radiation Oncology.

About iCAD, Inc.

iCAD is an industry-leading provider of Computer-Aided Detection (CAD)
technologies, advanced image analysis, workflow solutions and radiation
therapies for the early identification and treatment of common cancers. iCAD
offers a comprehensive range of high-performance, upgradeable CAD solutions
for mammography and advanced image analysis and workflow solutions for
Magnetic Resonance Imaging, for breast and prostate cancers and Computed
Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation
treatment for early-stage breast cancer that can be administered in the form
of Intraoperative Radiation Therapy or accelerated partial breast irradiation.
The Xoft System is also cleared for the treatment of non-melanoma skin cancer
and gynecological cancers. For more information, call (877) iCADnow, or visit

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of

Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to, the
Company’s ability to defend itself in litigation matters, the risks relating
to the Company’s acquisition of Xoft including, the expected benefits of the
acquisition may not be achieved in a timely manner, or at all; the Xoft
business operations may not be successfully integrated with iCAD’s and iCAD
may be unable to achieve the expected synergies, business and strategic
objectives following the transaction, the risks of uncertainty of patent
protection; the impact of supply and manufacturing constraints or
difficulties; product market acceptance; possible technological obsolescence;
increased competition; customer concentration; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”,
“likely”, and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under
no obligation to provide any updates to any information contained in this
release. For additional disclosure regarding these and other risks faced by
iCAD, please see the disclosure contained in our public filings with the
Securities and Exchange Commission, available on the Investors section of our
website at http://www.icadmed.com and on the SEC’s website at

Photos/Multimedia Gallery Available:



For iCAD investor inquiries:
Anne Marie Fields, 212-838-3777
For iCAD media inquiries:
Rachel Gross, 781-684-0770
Press spacebar to pause and continue. Press esc to stop.